BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 31783169)

  • 21. Not all stage I and II endometrial cancers are created equal: Recurrence-free survival and cause-specific survival after observation or vaginal brachytherapy alone in all subgroups of early-stage high-intermediate and high-risk endometrial cancer.
    Garzon S; Grassi T; Mariani A; Kollikonda S; Weaver AL; McGree ME; Petersen IA; Weroha SJ; Glaser GE; Langstraat CL; Amarnath SR; AlHilli MM
    Gynecol Oncol; 2022 Dec; 167(3):444-451. PubMed ID: 36244826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term results of 1-week intravaginal high-dose-rate brachytherapy alone for endometrial cancer.
    Gaztañaga M; Cambeiro M; Villafranca E; Vila M; Jurado M; Moreno M; Martínez-Monge R
    Brachytherapy; 2012; 11(2):119-24. PubMed ID: 21684815
    [TBL] [Abstract][Full Text] [Related]  

  • 23. American Brachytherapy Task Group Report: Adjuvant vaginal brachytherapy for early-stage endometrial cancer: A comprehensive review.
    Harkenrider MM; Block AM; Alektiar KM; Gaffney DK; Jones E; Klopp A; Viswanathan AN; Small W
    Brachytherapy; 2017; 16(1):95-108. PubMed ID: 27260082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant radiotherapy in Stage II endometrial carcinoma: Is brachytherapy alone sufficient for local control?
    Paydar I; DeWees T; Powell M; Mutch DG; Grigsby PW; Schwarz JK
    Brachytherapy; 2015; 14(4):427-32. PubMed ID: 25911995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Definitive salvage for vaginal recurrence of endometrial cancer: the impact of modern intensity-modulated-radiotherapy with image-based HDR brachytherapy and the interplay of the PORTEC 1 risk stratification.
    Vargo JA; Kim H; Houser CJ; Berhane H; Sukumvanich P; Olawaiye AB; Kelley JL; Edwards RP; Comerci JT; Huang M; Courtney-Brooks M; Beriwal S
    Radiother Oncol; 2014 Oct; 113(1):126-31. PubMed ID: 25241996
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of vaginal brachytherapy on survival in stage I endometrioid endometrial carcinoma.
    AlHilli M; Amarnath S; Elson P; Rybicki L; Dowdy S
    Int J Gynecol Cancer; 2020 Jun; 30(6):789-796. PubMed ID: 32184268
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy.
    Li JY; Park HS; Huang GS; Young MR; Ratner E; Santin A; Damast S
    Gynecol Oncol; 2021 Dec; 163(3):557-562. PubMed ID: 34602287
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sequential versus "sandwich" sequencing of adjuvant chemoradiation for the treatment of stage III uterine endometrioid adenocarcinoma.
    Lu SM; Chang-Halpenny C; Hwang-Graziano J
    Gynecol Oncol; 2015 Apr; 137(1):28-33. PubMed ID: 25666606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravaginal 1-week high-dose-rate brachytherapy alone for Stages I-II endometrial cancer.
    Martínez-Monge R; Nagore G; Cambeiro M; Garrán C; Villafranca E; Jurado M
    Brachytherapy; 2007; 6(3):195-200. PubMed ID: 17681240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multi-institutional Analysis of Vaginal Brachytherapy Alone for Women With Stage II Endometrial Carcinoma.
    Harkenrider MM; Martin B; Nieto K; Small C; Aref I; Bergman D; Chundury A; Elshaikh MA; Gaffney D; Jhingran A; Lee L; Paydar I; Ra K; Schwarz J; Thorpe C; Viswanathan AN; Small W
    Int J Radiat Oncol Biol Phys; 2018 Aug; 101(5):1069-1077. PubMed ID: 29885996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer: a controlled randomized study.
    Sorbe B; Nordström B; Mäenpää J; Kuhelj J; Kuhelj D; Okkan S; Delaloye JF; Frankendal B
    Int J Gynecol Cancer; 2009 Jul; 19(5):873-8. PubMed ID: 19574776
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant vaginal brachytherapy alone for high risk localized endometrial cancer as defined by the three major randomized trials of adjuvant pelvic radiation.
    McCloskey SA; Tchabo NE; Malhotra HK; Odunsi K; Rodabaugh K; Singhal P; Lele S; Jaggernauth W
    Gynecol Oncol; 2010 Mar; 116(3):404-7. PubMed ID: 19944453
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [High dose rate vaginal brachytherapy in endometrial cancer after surgery].
    Moreau-Claeys MV; Brunaud C; Hoffstetter S; Buchheit I; Peiffert D
    Cancer Radiother; 2011 Jun; 15(3):169-75. PubMed ID: 21237693
    [TBL] [Abstract][Full Text] [Related]  

  • 34. External radiotherapy versus vaginal brachytherapy for patients with intermediate risk endometrial cancer.
    Lin LL; Mutch DG; Rader JS; Powell MA; Grigsby PW
    Gynecol Oncol; 2007 Jul; 106(1):215-20. PubMed ID: 17482665
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lymphadenectomy in women with endometrial cancer: aspiration and reality from a radiation oncologist's point of view.
    Foerster R; Kluck R; Arians N; Rieken S; Rief H; Adeberg S; Bostel T; Schlampp I; Debus J; Lindel K
    Radiat Oncol; 2015 Jul; 10():147. PubMed ID: 26179059
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pelvic lymphadenectomy as an alternative to adjuvant radiotherapy in early stage endometrial cancer at high risk of recurrent lymphatic metastases (stage I)].
    Amato NA; Partipilo V; Mele F; Boscia F; De Marzo P
    Minerva Ginecol; 2009 Feb; 61(1):1-12. PubMed ID: 19204656
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvant Pelvic Radiation Therapy±Vaginal Brachytherapy in Patients With High-risk Stage I or Stage II Uterine Papillary Serous, Clear Cell, and High-grade Endometrioid Carcinoma.
    Nagar H; Yan W; Parashar B; Nori D; Chao KS; Christos P; Gupta D; Holcomb K; Caputo T; Wernicke AG
    Am J Clin Oncol; 2016 Aug; 39(4):335-9. PubMed ID: 27028349
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Salvage high-dose-rate brachytherapy and external beam radiotherapy for isolated vaginal recurrences of endometrial cancer with no prior adjuvant therapy.
    Chapman CH; Maghsoudi K; Littell RD; Chen LM; Hsu IC
    Brachytherapy; 2017; 16(6):1152-1158. PubMed ID: 28802913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Receipt of vaginal brachytherapy is associated with improved survival in women with stage I endometrioid adenocarcinoma of the uterus: A National Cancer Data Base study.
    Rydzewski NR; Strohl AE; Donnelly ED; Kanis MJ; Lurain JR; Nieves-Neira W; Strauss JB
    Cancer; 2016 Dec; 122(23):3724-3731. PubMed ID: 27509082
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravaginal high-dose-rate brachytherapy for stage I endometrial cancer: a randomized study of two dose-per-fraction levels.
    Sorbe B; Straumits A; Karlsson L
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1385-9. PubMed ID: 16029797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.